Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12631

    +

    P3.10-039 - Impact of Xanthine oxidoreductase and BRCA1 on prognosis of advanced Non-small cell Lung cancer (ID 2222)

    09:30 - 09:30  |  Author(s): S. Yalcin
    • Abstract

    Background
    Lung cancer is the leading cause of cancer-related deaths over the world. Treatment in locally advanced non small cell lung cancer (NSCLC) is heterogeneous. The cure rate after complate surgical resections not good as expected. Additional treatment have come into question. Cisplatin based chemotherapy adjuvant or neoadjuvant increases overall survival in stage III NSCLC. The better understanding of the biology of NSCLC, may allow selection of appropriate treatment. Only a few research is made about prognostic value of xanthine oxidoreductase (XOR) and BRCA-1 in lung cancer.

    Methods
    In our study, stage IIIA and stage IIIB 35 patients who had been followed in Baskent Universty medical oncology and of thoracic surgery departments, operated in Baskent Ankara and Adana hospitals, and who received neoadjuvant chemotherapy were included. Clinical and histopatological parameters (age, gender, stage, smoking history, performans status, neoadjuvant chemotherapy) along with immunohistochemical BRCA1and XOR staining were examinated and corelated with survival.

    Results
    Median overall survival time was 38.5 months and 5 year survival rate was 33% Patients with ECOG PS 0 had better overall survival than the patients with ECOG PS 2 (p= 0.004) According to results of the analyses for overall survival BRCA1 positivity was significant P=0.047, XOR was 0.039. The only significant associated parameter with overall survival was ECOG PS. There was no significant relation between overall survival and XOR expression in our patients.

    Conclusion
    BRCA1 positivity was associated with shorter overall survival in stage III lung cancer in patients to whom neoadjuvant platinium based chemotherapy was given.